Drugs Made In America Acquisition Corp.

Drugs Made In America Acquisition Corp. (Nasdaq: DMAAR) is a blank check company formed to pursue a merger or acquisition in the domestic pharmaceutical manufacturing sector. The company filed an amended registration statement (S-1/A) with the SEC on December 9, 2024, as it continued working through the regulatory review process ahead of its planned IPO. DMAAR's stated focus on domestic drug production reflects broader industry and policy interest in reshoring pharmaceutical supply chains within the United States, positioning the vehicle within the healthcare and life sciences SPAC landscape. Investors and analysts seeking full filing history, deal timelines, and comparable SPAC data can access comprehensive coverage by signing up at SpacDesk.